Dishman Carbogen Amcis Limited Announces Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017
January 24, 2018 at 03:25 am
Share
Dishman Carbogen Amcis Limited announced unaudited standalone and consolidated earnings results for the third quarter and nine months ended December 31, 2017. For the quarter, on standalone basis, the company reported Total income from operations of INR 950.6 million against INR 1,061.2 million a year ago. Profit before share of profit from associate & joint venture, exceptional items and tax was INR 192.2 million against loss of INR 54.6 million a year ago. Profit before tax was INR 192.2 million against loss of INR 54.6 million a year ago. Net profit was INR 117.4 million or INR 0.73 per basic and diluted share against loss of INR 35.3 million or INR 0.22 per basic and diluted share a year ago.
For the nine months, on standalone basis, the company reported total income from operations of INR 3,185.4 million against INR 3,234.5 million a year ago. Profit before share of profit from associate & joint venture, exceptional items and tax was INR 403.8 million against INR 84.8 million a year ago. Profit before tax was INR 403.8 million against INR 84.8 million a year ago. Net profit was INR 256.4 million or INR 1.59 per basic and diluted share against INR 43.2 million or INR 0.27 per basic and diluted share a year ago.
For the quarter, on consolidated basis, the company reported total income from operations of INR 4,598.2 million against INR 3,620.7 million a year ago. Profit before share of profit from associate & joint venture, exceptional items and tax was INR 680.6 million against INR 500.4 million a year ago. Profit before tax was INR 680.6 million against INR 496.7 million a year ago. Net profit was INR 420.0 million or INR 2.60 per basic and diluted share against INR 324.8 million or INR 2.01 per basic and diluted share a year ago.
For the nine months, on consolidated basis, the company reported total income from operations of INR 12,433.0 million against INR 11,794.7 million a year ago. Profit before share of profit from associate & joint venture, exceptional items and tax was INR 1,559.1 million against INR 1,335.8 million a year ago. Profit before tax was INR 1,559.1 million against INR 1,332.1 million a year ago. Net profit was INR 1,034.1 million or INR 8.41 per basic and diluted share against INR 951.3 million or INR 5.89 per basic and diluted share a year ago.
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Companyâs segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.
Dishman Carbogen Amcis Limited Announces Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017